8
NEWS
Doctors overlook obesity
Obesity must be recognized and treated as a disease. This was
the central message of the 23rd European Congress of Internal
Medicine (ECIM), held recently.
With the rapid rise of new anti-obesity medications, internists
at the congress explored the economic and health burdens of
obesity, recent advancements in pharmacological and surgical
treatments, effective lifestyle strategies, and the persistent stigma
associated with the condition.
During a workshop titled Adult Obesity Treatment Course for
Internists, organized by the European Association for the Study
of Obesity, discussions focused on patient experiences and the
significant roles of physical exercise and nutrition in managing
obesity. Despite strong evidence supporting these benefits, a gap
remains between theory and practice.
"Today, there are few specialists focused on prescribing
exercise, but I am confident that their numbers will continue to
grow. It is a step-by-step process that has just begun, but I believe
it will take hold," said Francesca Battista, a researcher from the
Department of Medicine, University of Padua in Padua, Italy.
Dexcom and ŌURA
Technology has come a long way
since the first blood glucose meter
was developed in 1965. Now, diabetes
patients have access to continuous
glucose monitors (CGMs), which
measure glucose levels in real time
and Dexcom currently occupies
around 74% of the CGM market share
in the US,
Products that are also generating
buzz in consumer healthcare are
smart rings, the most famous being
developed by Finland-founded
company ŌURA. ŌURA;s wearable
technology namesake smart
ring measures sleep, stress, and
cardiovascular data, among others.
Dexcom and ŌURA's partnership,
announced in November 2024, means
the two companies will enable data
flow between Dexcom and ŌURA
products, including Dexcom's glucose
biosensors and apps, as well as the
Oura Ring and accompanying app.
The first app integration is expected
to roll out in the first half of 2025.
Vitiligo management
Vitiligo is a complex dermatologic condition that requires a nuanced
approach to management. Various treatment options exist, each
with their own considerations regarding efficacy, safety, and patient
suitability. Furthermore, monitoring for treatment response and
progression is an important aspect of management, as the disease
is associated with significant effects on the quality of life, which
treatment side effects can worsen.
An online quiz has been launched which can help identify whether
vitiligo is being managed optimally. To take the quiz, CLICK HERE.
Mylife Loop
on iOS
Ypsomed and CamDiab are launching
an iOS version for the mylife CamAPS
FX app, which is part of the automated
insulin delivery system mylife Loop. This
allows people with Type 1 diabetes to
easily and discreetly manage mylife Loop
on their iPhones.
The rollout of mylife Loop on iOS
will begin on 24 March 2025 in Sweden
and will subsequently be expanded to
other countries. During the pilot phase
in Sweden, mylife Loop will initially be
available with the FreeStyle Libre 3 and
FreeStyle Libre 3 Plus sensors from
Abbott. The integration of the Dexcom
G6 sensor into the mylife CamAPS FX
app will follow. After the successful pilot
launch, the rollout of mylife Loop on iOS
will continue across Europe followed by
Australia and Canada throughout 2025.
To find out more, CLICK HERE.